Dr. Eric Raab and Gregory Riggins are pioneering the use of Palbociclib PD-1 and Mebendazole to treat brain cancers. Dr. Eric Raabe: Our group is working on creating a Group 4 medulloblastoma model that can be used for drug testing. We already know they frequently have CDK4/6 alterations (meaning they are likely susceptible to palbociclib). We know that MYC-expressing medullo is better at hiding from the immune system (and more reliant on PDL-1 to do this), making it a good candidate for PD-1 blockade. We have normal cerebellar neural stem cells, and we are interested in creating a Group 4 model by adding oncogenes to this model (we have done this successfully for MYC-driven medullo (Group 3). Having an accurate model will be key to finding new therapies.